Table 5.
Cost-effectiveness results and cost breakdown, base case
| LAMA + roflumilast | LAMA | Incremental | LABA/ICS + roflumilast | LABA/ICS | Incremental | LAMA + LABA/ ICS + roflumilast | LAMA + LABA/ICS | Incremental | |
|---|---|---|---|---|---|---|---|---|---|
| Total cost, CHF | 86,754 | 83,364 | 3390 | 91,470 | 88,161 | 3308 | 99,364 | 95,564 | 3799 |
| Cost of maintenancea, CHF | 35,857 | 25,481 | 10,376 | 40,917 | 30,279 | 10,638 | 48,533 | 37,682 | 10,851 |
| Cost of community-treated exacerbations, CHF | 2039 | 2331 | −292b | 2025 | 2331 | −306b | 2036 | 2331 | −295b |
| Cost of hospital-treated exacerbations, CHF | 48,858 | 55,552 | −6694b | 48,528 | 55,552 | −7024b | 48,795 | 55,552 | −6757b |
| Life years (LY) | 9.625 | 9.278 | 0.347 | 9.642 | 9.278 | 0.364 | 9.628 | 9.278 | 0.351 |
| Quality-adjusted life years (QALY) | 6.466 | 6.191 | 0.275 | 6.479 | 6.191 | 0.289 | 6.468 | 6.191 | 0.278 |
| ICER, CHF per QALY | 12,313 | 1 1,456 | 13,671 | ||||||
| ICER, CHF per LY | 9757 | 9078 | 10,833 |
Notes:aCost of maintenance includes the monthly medical services, and the cost of COPD drugs;
b
cost offset (reduction in the roflumilast arm).
Abbreviations: LAMA, long-acting muscarinic antagonists; LABA, long-acting beta-agonists; ICS, inhaled corticosteroids; ICER, incremental cost-effectiveness ratio.